Riskpilot← Back to searchSign inGet full accessPHARMA HOLDINGS AS
ASActiveOrg 917999244Killengreens Gate 8, 9008 TromsøResearch and experimental development on natural sciences and engineering · NACE 7210Est. 20165 employees
Revenue 2024
NOK 120K
-93% vs 2023
EBITDA margin
-14827.3%
-18% vs 2023
Equity ratio
85.9%
Financial strength
Net profit 2024
NOK -17,6M
-16% vs 2023
| Revenue | NOK 120K | -93% |
| EBITDA | NOK -17,8M | -18% |
| Net profit | NOK -17,6M | -16% |
| Total assets | NOK 9,5M | -55% |
| Equity | NOK 8,2M | -50% |
| Employees | 5 | — |
Legal name
PHARMA HOLDINGS AS
Org number
917999244
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
4. november 2016
Share capital
NOK 1 353 505
Employees
5 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
To styremedlemmer i fellesskap. Styrets leder alene.
Company purpose
Utvikling, markedsføring og salg av medisinske, kjemiske og bioteknologiske produkter, samt dertil hørende virksomhet. Selskapet kan ha eierinteresser i foretak innen samme eller tilstøtende bransjer.
Address
Killengreens Gate 8, 9008 Tromsø
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 3 384 | 6 618 | 4 644 | 1 741 | 120 |
| Staff expenses | −987 | −1 814 | −4 672 | −4 484 | −3 510 |
| EBITDA | −6 220 | −13 776 | −25 715 | −15 082 | −17 793 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −6 220 | −13 776 | −25 715 | −15 082 | −17 793 |
| Net financials | 9 | 30 | −1 342 | −92 | 198 |
| Profit before tax | −6 211 | −13 746 | −27 057 | −15 174 | −17 595 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −6 211 | −13 746 | −27 057 | −15 174 | −17 595 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 6 514 | 7 077 | 18 047 | 21 133 | 9 497 |
| Equity | 4 926 | 6 180 | 15 427 | 16 353 | 8 158 |
| Long-term debt | 0 | 0 | 102 | 102 | 102 |
| Short-term debt | 1 588 | 897 | 2 518 | 4 677 | 1 237 |
| Total debt | 1 588 | 897 | 2 621 | 4 780 | 1 339 |
EBITDA margin
-14827.3%
This company
15.8%
Market median
-93944% vs market
20202024
Equity ratio
85.9%
This company
38.2%
Market median
+125% vs market
20202024
Return on equity
-215.7%
This company
18.4%
Market median
-1272% vs market
20202024
Net profit margin
-14662.7%
This company
8.1%
Market median
-181121% vs market
20202024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20202024
Debt / equity
0.16×
This company
0.62×
Market median
+74% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
CG Chief Executive Officer | Chief Executive Officer | 2021 |
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Board of Directors | 2024 | |
| Chairman | 2022 | |
| Board of Directors | 2022 | |
| Board of Directors | 2024 | |
| Former (2) | ||
| Board of Directors | 2022 – 2024 | |
| Board of Directors | 2022 – 2022 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 44.28% | 44.28% | 2024 | |
| Company | 11.62% | 11.62% | 2024 | |
| Company | 6.21% | 6.21% | 2024 | |
| Company | 5.39% | 5.39% | 2024 | |
| Company | 5.25% | 5.25% | 2024 | |
| Company | 5.03% | 5.03% | 2024 | |
| Company | 4.46% | 4.46% | 2024 | |
| Individual | 2.17% | 2.17% | 2022 | |
| Company | 2.11% | 2.11% | 2024 | |
| Company | 1.28% | 1.28% | 2023 | |
| Company | 1.09% | 1.09% | 2024 | |
| Company | 1.09% | 1.09% | 2024 | |
| Individual | 1.05% | 1.05% | 2024 | |
| Company | 1.05% | 1.05% | 2024 | |
| Individual | 1.02% | 1.02% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Kaupaloki As
PHARMA HOLDINGS AS Board members of PHARMA HOLDINGS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Christian Georg Lütken | Chief Executive Officer | 0 companies |
| Per Erik Sørensen | Board of Directors | 0 companies |
| Sidey Agneta Christina Svedberg | Board of Directors | 0 companies |
| Bernt Endrerud | Chairman | 0 companies |
| Håvard Selby Ebbestad | Board of Directors | 0 companies |
| Cecilia Ann-Christin Malmborg Hager | Board of Directors | 0 companies |
| Øyvind Kongstun Arnesen | Board of Directors | 0 companies |